Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Endo Health Solutions (ENDP - Analyst Report) appears to be a great believer in the growth-by-acquisition strategy. The company has been quite active on the acquisition front over the last few years. Endo Health completed three major acquisitions in 2010 to bolster its business. In Dec 2010, the company acquired Qualitest Pharmaceuticals for $1.2 billion. During 2010, Endo also bought Penwest Pharmaceuticals Co. and HealthTronics Inc. In Jun 2011, the company purchased American Medical Systems, a leading pelvic-health devices provider, for $2.9 billion.

The company inked a couple of deals in 2012 to expand its business. In Mar 2012, Endo Health joined hands with Mersana Therapeutics Inc. for the development of next-generation antibody-drug conjugates. Moreover, in Jan 2012, Endo inked a global license and development agreement with BioDelivery Sciences International regarding the latter’s pain candidate BEMA buprenorphine.

Endo Health has signed a few acquisition related deals in 2013 too. In Aug 2013, Endo announced its intention to acquire privately-held generics company Boca Pharmacal for $225 million in cash. Earlier in the month, Endo Health announced its decision to acquire NuPathe Inc. for an upfront cash payment of $2.85 per share or about $105 million. Endo Health expects significant cost synergies from the acquisition, expected to be completed in early 2014. The NuPathe acquisition is expected to be earnings-accretive within a year of the closing of the transaction.

However, the most expensive acquisition related announcement at Endo Health was made in Nov 2013 when it decided to announce Canadian Specialty Pharmaceutical Company Paladin Labs Inc. for approximately $1.6 billion in a cash and stock deal. Endo Health moved a step closer to acquiring Paladin when the former announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976. Moreover, the Canadian Competition Bureau issued a no-action letter removing another hurdle related to the impending acquisition.

At the time of announcing the deal, Endo Health had said that the deal, following closure, is expected to result in annual savings of at least $75 million. Shareholders at Endo Health will own 77.5% of the merged entity and Paladin Labs shareholders will hold the balance. Endo Health’s current management will head the operations of the merged entity.

We believe that the impending acquisitions are in line with Endo Health’s efforts to expand and counter the declining revenues due to generic competition facing its key drugs.

Endo Health carries a Zacks Rank #2 (Buy). Investors may consider stocks like Jazz Pharmaceuticals (JAZZ - Analyst Report) and Vanda Pharmaceuticals Inc. (VNDA - Snapshot Report). Both stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.25 +10.59%
MODINE MANUF MOD 17.12 +8.77%
CLAYTON WILL CWEI 140.03 +7.27%
E*TRADE FINA ETFC 22.67 +5.44%
KNIGHTSBRIDG VLCCF 13.22 +5.42%